Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phosphatidylcholine vs Mesalazin for Remission Maintenance in Ulcerative Colitis
NCT00259571Phase 3Withdrawn
- Sponsor
- Heidelberg University
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of phosphatidylcholine in ulcerative colitis (UC) (2 arms), sponsored by Heidelberg University. Primary endpoints: Rate of relapses and Increase of clinical Rachmilewitz index to 5 or more at 14 days. Status: withdrawn.
02
Drugs
phosphatidylcholine
03
Conditions
ulcerative colitis (UC)
Beyond the preview
Go deeper on NCT00259571.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00259571.